April 20, 2015
BioCentury Article: ASF And FAST To Collaborate With Ovid Therapeutics.
Ovid is working with patients and families to develop failed drugs for rare and Orphan brain diseases, starting with Angelman syndrome . . .
Read more 
December 1, 2014
Possible Therapeutic for Angelman Syndrome
ASF-Funded Research Discovers Possible Therapeutic for Angelman Syndrome Promising ASF-funded research continues to move closer toward possible clinical trials, as announced today in a paper in Nature by Dr. Art Beaudet and his research team at Baylor College of Medicine. The ASF […]
Read more
November 17, 2014
Research at UNC Making Progress
PNAS Paper shows ASF-funded Research at UNC Making Progress The ASF continues to lead the charge in funding research that is making progress towards treatments and ultimately a cure for Angelman syndrome, having invested more than $8 million during the […]
Read more
October 22, 2014
Angelman Syndrome Clinics across the U.S.
ASF invests $1.5 million to support 17 Angelman Syndrome Clinics across the U.S. Furthering its direct support of individuals with Angelman syndrome and their families, the Angelman Syndrome Foundation has committed $1.5 million to establish 17 comprehensive Angelman Syndrome Clinics across the […]
Read more
August 3, 2014
Reducing Seizures in Angelman Syndrome
Dietary Treatment Proven Successful in Reducing Seizures in Angelman Syndrome by up to 90 Percent The Angelman Syndrome Foundation (ASF) is very excited to announce today that clinical research published in Epilepsia on July 10 has found that a low glycemic index […]
Read more
January 9, 2014
AS Research at Baylor University Makes Significant Progress
AS research at Baylor University Seeking Viable Treatment Makes Significant Progress The Angelman Syndrome Foundation and the lab of Arthur Beaudet, M.D., at Baylor University are inspired and excited to announce that progress is being made in analyzing a possible […]
Read more
August 28, 2013
Research on Topoisomerase Inhibitors
University of North Carolina-Chapel Hill Research Overview and Frequently Asked Questions The Angelman Syndrome Foundation previously supported breakthrough research showing that topoisomerase inhibitors—specifically, topotecan, an FDA-approved drug used in cancer treatments—activates the paternal allele of Ube3a, identifying a possible treatment […]
Read more
June 18, 2013
ASF Invests $1.25 Million in Research
Angelman Syndrome Foundation Invests $1.25 Million in Research The Angelman Syndrome Foundation (ASF) announced today that because of the generosity of its supporters the organization has awarded $1.25 million to six research grants focused on finding treatments and defining the […]
Read more